Skip to content
Meta-analysis Open access

Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 108 references
Medicine

TL;DR

Higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICI therapy, with the most consistent favorable association observed for obesity, warranting cautious interpretation.

Abstract

Background Pretreatment body mass index (BMI) has been associated with outcomes during immune checkpoint inhibitor (ICI) therapy, but study-specific categories and incomplete adjustment complicate interpretation. We evaluated associations with efficacy and toxicity across tumor types and BMI definitions. Methods We searched the Cochrane Library, Embase, PubMed, and Web of Science from inception through November 30, 2025. Random-effects models pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for objective response rate (ORR) and immune-related adverse events (irAEs). Adjusted estimates defined the primary analyses. We also evaluated category-specific contrasts, clinical subgroups, cutoff meta-regression, and linear dose-response associations per 5-kg/m2 increase in BMI. Results Sixty-one studies involving 46,572 patients were included. Higher BMI was associated with a lower adjusted hazard of death (HR = 0.74, 95% CI: 0.67-0.82, P < 0.001; I2 = 70.6%; 95% prediction interval: 0.48-1.13) and a lower adjusted hazard of progression or death (HR = 0.78, 95% CI: 0.69-0.89, P < 0.001; I2 = 60.3%; 95% prediction interval: 0.47-1.32). However, both prediction intervals included the null value. Category-specific analyses showed that obesity, but not overweight, was associated with improved OS and PFS relative to normal weight. BMI cutoff did not significantly moderate either endpoint. Per 5-kg/m2 increase in BMI, adjusted PFS improved (HR = 0.87, 95% CI: 0.81-0.95, P < 0.001; I2 = 47.7%), whereas OS did not (HR = 0.91, 95% CI: 0.81-1.01, P>0.05; I2 = 64.0%). Adjusted associations with ORR and any-grade irAEs were not significant, and evidence for grade 3 or higher irAEs was insufficient. Conclusion In this systematic review and meta-analysis, higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICIs, with the most consistent favorable association observed for obesity. However, the prediction intervals included the null value, and associations with treatment response and irAEs remained inconsistent, warranting cautious interpretation.

Read PDF

Similar papers

Meta-analysis Open access Sep 2026

Overall survival with immune checkpoint inhibitors across treatment settings and clinical and PD-L1-defined subgroups in advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of randomized trials

ICI-containing regimens improved overall survival in both first- and later-line settings, but aggregate within-trial interaction analyses did not identify a reliable clinical or PD-L1-defined treatment-effect modifier.

Bing Wang, Xiao-Yu Han, Zeng-Li Shen · 0 citations
Open access Aug 2026

Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1/PD-L1 Inhibitors: A Prospective Exploratory Study

Background/Objectives: Immunotherapy using immune checkpoint inhibitors has transformed the treatment of multiple solid tumours. However, the clinical response to programmed death receptor (PD-1) and its ligand (PD-L1) inhibitors remains heterogeneous. We have previously shown that host-related factors such as body mas...

A. Morell, A. Morell, Ainhoa Aranguren et al. · 0 citations
Review Open access Sep 2026

Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Background Immune checkpoint inhibitors combined with chemotherapy have improved pathological responses in early-stage triple-negative breast cancer (TNBC), but the magnitude of benefit and associated toxicity remain variable across trials. This systematic review and meta-analysis aimed to evaluate the efficacy and saf...

Jia-Le Li, Pei-Tao Wu, Jing-Shu Song et al. · 0 citations
Review Open access Oct 2026

Immune-related adverse events are associated with favorable clinical outcomes in esophageal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis

In patients with EC receiving ICIs, the occurrence of irAEs may be a prognostic marker of favorable outcomes, however, wide PIs for PFS and ORR indicate that these associations may vary across future studies and immortal time bias may overestimate survival associations.

Jian-Jiang Fan, Dong-Mei Chen, Li-Qun Jia · 0 citations
Open access Aug 2026

Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study

Neoadjuvant disitamab vedotin plus PD-1 blockade showed promising antitumor activity and the pooled CR endpoint may overestimate pathological response and is not directly comparable with cystectomy-confirmed pCR.

Yong-Sheng Huang, Yongpeng Ji, Xiao Yang et al. · 0 citations
Open access Sep 2026

Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?

Background Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non–small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)—including their cumulative burden—across age groups is not fu...

A. Agbarya, N. S. Shrem, Asmah Miari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.